Ortho Clinical Diagnostics
In the wake of suspending guidance to review the business in the first quarter of the year, QuidelOrtho has restructured and resumed offering a financial outlook.
QuidelOrtho Revenues up 8 Percent in Q2
On a conference call, its CEO said the future menu for the Savanna instrument will include respiratory panels, panels for other STDs, a panel for GI infections, and other tests.
JP Morgan Healthcare Conference, Day 1: Guardant Health, Exact Sciences, Bruker, 10x Genomics, More
Highlights from the first day included Exact Sciences' profitability forecast, an update on QuidelOrtho's integration, and Guardant Health's "quantum leap forward" with its "smart" liquid biopsy platform.
QuidelOrtho Preliminary Q4 Earnings Beat Estimates
The firm expects its Q4 non-COVID core revenues to increase approximately 18 percent and full-year core revenues to increase approximately 11 percent.
The firm also said it will shift its near-term regulatory and commercial strategy for its Savanna molecular diagnostic instrument.